Navigation Links
H. pylori vaccine shows promise in mouse studies
Date:12/19/2013

Researchers from Southern Medical University in Guangdong, Guangzhou, China, have developed an oral vaccine against Helicobacter pylori, the bacteria responsible for peptic ulcers and some forms of gastric cancer, and have successfully tested it in mice. The research is published ahead of print in the journal Clinical and Vaccine Immunology.

The investigators constructed a live recombinant bacterial vaccine, expressing the H. pylori antigen, adhesin Hp0410, in the food-grade bacterium, Lactobacillus acidophilus. They then used it to orally vaccinate the mice.

The vaccine elicited specific anti-Hp0410 IgG antibodies in serum, and showed "a significant increase" in the level of protection against gastric Helicobacter infection, according to the report. When assayed, following challenge with H. pylori, immunized mice had significantly lower bacterial loads than non-immunized mice.

H. pylori is a class 1 human carcinogen, according to the World Health Organization. It causes gastritis, peptic ulcers, stomach cancer, and mucosa-associated lymphoid tissue lymphoma. Antibiotic therapy is complex, unsuccessful in some patients (particularly in developing countries) and relapse is common. A vaccine against H. pylori could circumvent these difficulties.

L. acidophilus, a bacterium which is common in yogurt cultures, has distinct advantages as an oral vaccine antigen delivery vehicle. It is safe and nontoxic. It resists the stomach's acidity and tolerates bile, all of which aids in enabling it to survive in the gastrointestinal (GI) tract for more than 72 hours. Additionally, it adheres to, and elicits an immune response from the GI tract mucosa.

The current first-line treatment option for H. pylori infection includes two antibiotics and a proton pump inhibitor, but is ineffective in roughly 20 percent of patients.

"The high cost of treatment, noncompliance, and antibiotic resistance are the most important reasons," says first author Fan Hongying.

Roughly 15-30 percent of patients relapse quickly, she says, noting that after treatment, H. pylori may be resupplied to the stomach from a reservoir in the mouth. A vaccine would circumvent these problems.

"Our results collectively indicate that adhesin Hp0410 is a promising candidate vaccine antigen and recombinant Lactobacillus acidophilus expressing Hp0410 is likely to constitute an effective, low-cost live bacterial vaccine against H. pylori," says Hongying.


'/>"/>

Contact: Jim Sliwa
jsliwa@asmusa.org
202-942-9297
American Society for Microbiology
Source:Eurekalert

Related biology news :

1. Ironing out the link between H. pylori infection and gastric cancer
2. Special issue of Gut Microbes on Helicobacter pylori
3. Queens scientists seek vaccine for Pseudomonas infection
4. In search for a vaccine, IU biologist receives $2.3 million to explore chlamydia genomics
5. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
6. SFU HIV/AIDS vaccine research gets financial boost
7. Researchers identify Achilles heel of dengue virus, target for future vaccines
8. AAPS National Biotechnology Conference to highlight innovative vaccines
9. Army study: DNA vaccine and duck eggs protect against hantavirus disease
10. Sensitive test helps improve vaccine safety
11. Overweight? Theres a vaccine for that
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... NEW YORK , March 21, 2017 /PRNewswire/ ... Customer Marketing Cloud used by retailers such as ... in its platform — Product Recommendations and Replenishment. Using ... to give more personalized product and replenishment recommendations ... purchases, but also on predictions of customer intent ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in ... ... combined in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification ... Used combined in one project, multi-biometric solutions provide a ... ...
(Date:3/7/2017)... , March 7, 2017 Brandwatch , the ... by The Prince,s Trust to uncover insights to support ... The Trust. The UK,s leading youth charity will be ... campaign results and get a better understanding of the topics and ... ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... Lilly and Company (NYSE: LLY ) will ... of migraine at the American Academy of Neurology (AAN) ... in Boston . ... and patient outcomes data for galcanezumab in patients with ... migraine headache days among patients with episodic migraine. Lilly ...
(Date:4/20/2017)... Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the ... ("ILC") 2017 of the European Association for the Study of ... the positive effects of PBI-4050 on reduction of non-alcoholic steatohepatitis ... ... Gagnon, Vice-President of R&D Pre-clinical of Prometic "This extensive preclinical ...
(Date:4/20/2017)... philosopher Koert van Mensvoort - founder of the Next Nature Network ... - has written a ,Letter to Humanity, in support of International ... slave and victim to its own technology, but to employ technology to enhance ... ... founder of the Next Nature Network and Fellow of ‘Next Nature’ at the ...
(Date:4/19/2017)... ... 18, 2017 , ... A number of new instruments have recently emerged to ... the Protein and Cell Analysis Education Webinar Series , will focus on advances ... current and future applications. , Many flow cytometers have unique capabilities and the ...
Breaking Biology Technology: